|
|
Post by iamaverb on Aug 19, 2015 17:36:39 GMT
Let the short covering commence!
|
|
|
|
Post by harlem on Aug 19, 2015 17:50:48 GMT
Did some buying today glta
|
|
|
|
Post by CM kipper007 on Aug 19, 2015 18:26:57 GMT
Deadally ripped that guy a new arsehole in the comments section of that SA article today.
So funny.
|
|
|
|
Post by deadally on Aug 19, 2015 18:34:37 GMT
Deadally ripped that guy a new arsehole in the comments section of that SA article today. So funny. My one regret is not taking it the full distance it deserved. But I only have so many hours in a day to waste. |
|
|
|
Post by Whidbeygal CM 20/20 on Aug 19, 2015 18:40:24 GMT
Deadally ripped that guy a new arsehole in the comments section of that SA article today. So funny. I usually refrain from commenting on SA articles----but Deadally's response was absolutely perfect. |
|
|
|
Post by dayanand33 on Aug 19, 2015 18:48:26 GMT
Agree, complete garbage.
I only skimmed it, but when I saw a statement from the author that OCAT had only monitored the treated patients for 12 months (a lie) and that the therapy was highly likely to cause tumors, I stopped skimming. Joke of an article.
I am highly suspicious of the intent behind writing this article, especially because it has a lot of blatant lies wrapped around a small kernel of truth. The below article speaks about such manipulation techniques. smithonstocks.com/illegal-naked-short-selling-appears-to-lie-at-the-heart-of-an-extensive-stock-manipulation-scheme/"Seeking Alpha has become very friendly to articles supporting short selling and is used extensively by the hedge funds. The site actually promotes as one of its favorite authors a person who writes only negative attack article on companies in which he claims that managements are lying and paying authors who have a positive view on the Company. In his disclosure, he states that he shorts stocks, then publishes a negative article on Seeking Alpha and states that he may cover immediately after the article is published. This seems to meet the definition of a pump and dump scheme. He also acknowledges that he is collaborating with other short sellers. I think they contribute the information for most of his articles
Seeking Alpha allows articles to be published by anonymous authors. These articles are often extremely bearish and are almost certainly written by people at hedge funds" |
|
|
|
Post by thechurchmaus on Aug 19, 2015 18:56:43 GMT
can the reputation of SA and its writers sink any lower?the market obviously deems them irrelevant.
|
|
|
|
Post by demondeacon on Aug 19, 2015 19:25:41 GMT
First purchase in quite some time at $3.23. I may be foolish, but I'm taking Ocata's decision (and more importantly their ability) to secure debt financing over dilution (at least near-term) as management finally acknowledging the company is "cheap." en.wikipedia.org/wiki/Pecking_order_theoryHoping to find a nice exit point after shares recover to $4.00 - $5.00. This time I just need to actually follow through on the "get out" part. |
|
|
|
Post by iamaverb on Aug 19, 2015 20:03:35 GMT
Was today's volume of 960,101 a historic high?
|
|
|
|
Post by actcfan on Aug 19, 2015 20:11:14 GMT
Was today's volume of 960,101 a historic high? No, it has been higher. It was higher just a few weeks back on 7/31/15 |
|
|
|
Post by imz72 on Aug 19, 2015 20:24:07 GMT
Was today's volume of 960,101 a historic high? No, it has been higher. It was higher just a few weeks back on 7/31/15 Since June 1st OCAT had 4 days of higher volume: Jun 17, 2015 - 2,572,700 Jun 19, 2015 - 1,066,500 Jun 26, 2015 - 5,194,600 Jul 31, 2015 - 967,600 finance.yahoo.com/q/hp?s=OCAT&a=05&b=01&c=2015&d=07&e=19&f=2015&g=d |
|
|
|
Post by RLC on Aug 19, 2015 20:57:56 GMT
Agree, complete garbage.
I only skimmed it, but when I saw a statement from the author that OCAT had only monitored the treated patients for 12 months (a lie) and that the therapy was highly likely to cause tumors, I stopped skimming. Joke of an article.
Between the comments on the article and the PPS action today.... I'd say the author is feeling pretty lousy (especially if he/she truly has a short position on OCAT). Congrats to all holding for the small victory today! OCAT and it's shareholders desperately needed a day like today. The move today was on high volume and in a nasty market... very impressive. |
|
|
|
Post by ignorantsilver on Aug 19, 2015 21:46:30 GMT
looks like somebody is manipulating the price up today...this turd should be at 50 cent  |
|
|
|
Post by jckrdu on Aug 19, 2015 22:09:28 GMT
looks like somebody is manipulating the price up today...this turd should be at 50 cent While we don't get many opportunities to talk about this with OCAT, gaps get filled on the way up too. 
Gap in OCAT's chart from $5.45 to $6.23.
Odds are that gap fills before the end of the year, after Phase 2 starts and some other news is released.
|
|
|
|
Post by iamaverb on Aug 20, 2015 0:30:16 GMT
looks like somebody is manipulating the price up today...this turd should be at 50 cent While we don't get many opportunities to talk about this with OCAT, gaps get filled on the way up too.
Gap in OCAT's chart from $5.45 to $6.23.
Odds are that gap fills before the end of the year, after Phase 2 starts and some other news is released.
We can always hope to follow in Sarepta's footprints. "After hitting an all-time low with a closing stock price of 61 cents on July 5, 2012 of , the biopharmaceutical company renowned for its work in the treatment of infectious diseases in 2015, rebranded its name from AVI BioPharma (Nasdaq: AVII) to Sarepta Therapeutics, Inc. (Nasdaq: SRPT)." "By July 24, 2012, the first part of the Phase II clinical trial at 36 weeks showed patients treated with Eteplirsen were able to walk an average of 69.4 meters. By the NYSE close, Sarepta’s stock increased to $8.52, with a trading volume of 16.8 million shares. Sarepta’s stock price had slow increases for the next few months until Oct. 3, 2012, when its Phase IIb clinical trial observed a turn of events." "In a public conference call, Sarepta announced that after 48 weeks, patients treated with Eteplirsen had not only increased dystrophin levels by 47 percent, but proved Eteplirsen’s clinical benefit since patients with DMD demonstrated their ability to walk an average of 89.4 meters in six minutes. Sarepta’s stock price jumped from closing on Oct. 2, 2012 at $12.99 to closing on Oct. 3, 2012 at $44.93."
|
|
|
|
Post by RLC on Aug 20, 2015 1:05:42 GMT
What's up with 2 Alpha articles and a company loan agreement all coming out on the same day. Is there something else in the wings driving this exposure whether it be good or bad. Being that it is my birthday I am expecting something to brighten my day...............of course turning another year older is not helping anything. Ya it is a bit of a coincidence. I hope the 12% bump brightened your day today! Aging is a b*tch! Hopefully stem cells can help ease the process a bit in the near future  Happy bday sell! |
|
|
|
Post by selluwud on Aug 20, 2015 1:47:32 GMT
What's up with 2 Alpha articles and a company loan agreement all coming out on the same day. Is there something else in the wings driving this exposure whether it be good or bad. Being that it is my birthday I am expecting something to brighten my day...............of course turning another year older is not helping anything. Ya it is a bit of a coincidence. I hope the 12% bump brightened your day today! Aging is a b*tch! Hopefully stem cells can help ease the process a bit in the near future Happy bday sell! Thanks, my family made sure I had a great birthday. OCAT making a move was nice but I've learned from experience not to count my chickens until they are fried and on the platter. I am a firm believer that stem cell thereapies are going to be one of the next major turning points in health care with the future beyond that outside of our current ability to comprehend. |
|
|
|
Post by guruzim on Aug 20, 2015 3:33:42 GMT
Deadally: simply, thanks.
|
|
|
|
Post by ymc on Aug 20, 2015 6:59:50 GMT
Gap filled.
I'm going to hold off adding more until after I see the Fed minutes at 2:00 PM EST today. That event could tank the market and the Biotech sector... or fuel a rally.
Nice to see OCAT bounce up hard after the gap was filled. Good chance $3.06 was the bottom.... with Phase 2 starting very soon. Yeah, the $3.06 is a test of last Friday's bottom. the 52 week low. Wasn't a weak bounce either, with more than 10% of the avg daily volume in one minute. Another good news is that the stem cell group performs better than the overall biotech sector two days in a row. Figure that! |
|
|
|
Post by oceans on Aug 20, 2015 8:16:32 GMT
EDIT: **** Oceans, you pasted an entire Seeking Alpha article here (albeit from icell) - not sure we want to post whole articles to this forum from places like that, especially inflammatory articles. Seeking Alpha makes money from page views so they would likely have issues with it being copied here. Hope you understand why I've removed it. The article is still available to be viewed on SA last I checked. Won't be shocked if they take it down though. Thanks, actcfan ****
|
|
